WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.

Richer, Amanda L

WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer. [electronic resource] - Cancer research 09 2017 - 4663-4672 p. digital

Publication Type: Journal Article

1538-7445

10.1158/0008-5472.CAN-16-3565 doi


AMP-Activated Protein Kinases
Animals
Carcinoma, Non-Small-Cell Lung--drug therapy
Cell Cycle Checkpoints--drug effects
Cell Cycle Proteins--antagonists & inhibitors
Cell Survival--drug effects
Drug Evaluation, Preclinical
Female
Humans
Lung Neoplasms--drug therapy
Male
Mice
Mice, Transgenic
Mutation--genetics
Nuclear Proteins--antagonists & inhibitors
Phosphorylation--drug effects
Protein Serine-Threonine Kinases--deficiency
Protein-Tyrosine Kinases--antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)--genetics
Pyrazoles--pharmacology
Pyrimidines--pharmacology
Pyrimidinones
Tumor Cells, Cultured